Category: Heart failure

A 2022 guideline on heart failure management emphasizes that when transitioning a patient from an ACE inhibitor to the drug Entresto, a minimum of 36 hours must elapse between the last dose of one and the first dose of the other. This 36 hour washout period is a vital safety protocol to prevent a potentially catastrophic drug-drug interaction.

While manufacturer labeling often restricts intravenous milrinone to a short-term, 48-hour hospital stay for acute heart failure, real-world clinical practice uses it for significantly longer durations in specific circumstances. The question, "**How long can a person stay on milrinone?**," is complex and depends heavily on the individual's clinical condition and treatment goals.

Approximately 6.7 million adults in the United States have heart failure [1.10.1]. For these individuals, understanding **which of the following medications is contraindicated in a patient with heart failure** is critical for preventing worsening symptoms and hospitalizations. Many common drugs can be harmful.